NETTER-1
¹⁷⁷Lu-DOTATATE transformed midgut neuroendocrine tumor therapy, the trial behind Lutathera
Quick Answer
NETTER-1 (Strosberg et al., N Engl J Med 2017) was the phase 3 randomized trial that established ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) for progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. It produced a large improvement in progression-free survival over high-dose octreotide and directly supported the FDA/EMA approval of Lutathera — the trial that made SSTR theranostics a standard of care.
The trial
Design: phase 3, 229 patients with well-differentiated, progressive, SSTR-positive midgut (small-intestinal) NETs that had progressed on standard-dose somatostatin analogue. Randomized to ¹⁷⁷Lu-DOTATATE (7.4 GBq × 4 cycles, every 8 weeks, with amino-acid renal protection) plus octreotide LAR versus high-dose octreotide LAR (60 mg). Primary endpoint: progression-free survival (PFS).
Key result
PRRT produced a marked PFS benefit — median PFS was not reached (≈ estimated 28+ months) versus 8.4 months for high-dose octreotide, a hazard ratio ≈ 0.21 (roughly a 79% reduction in progression/death). Response rates were higher, and quality-of-life measures favored PRRT. The final overall-survival analysis showed a numerical but not statistically significant benefit (the trial was not powered for OS after crossover).
Why it mattered
NETTER-1 was the first phase 3 randomized trial of PRRT and the pivotal evidence behind ¹⁷⁷Lu-DOTATATE (Lutathera) approval. It validated the somatostatin-receptor theranostic pair — SSTR imaging (DOTATATE PET) to select patients, then the matched ¹⁷⁷Lu radioligand to treat — and established amino-acid renal protection as standard practice.
Context & caveats
NETTER-1 studied midgut NETs specifically; the later NETTER-2 trial extended ¹⁷⁷Lu-DOTATATE to the first-line setting in higher-grade (grade 2–3) GEP-NETs. Kidney and bone marrow are the dose-limiting organs, and PRRT requires confirmed SSTR expression on imaging.
Self-Check
Q1. What did NETTER-1 establish, and in which tumors?
Answer: That ¹⁷⁷Lu-DOTATATE PRRT markedly improves PFS in progressive, SSTR-positive midgut neuroendocrine tumors — the basis for Lutathera's approval.
Q2. What was the magnitude of the PFS benefit?
Answer: Median PFS not reached vs 8.4 months (HR ≈ 0.21) versus high-dose octreotide — a large effect.
Q3. What supportive measure did NETTER-1 embed as standard PRRT practice?
Answer: Amino-acid renal protection (co-infused to reduce kidney dose), with 7.4 GBq × 4 cycles.
Q4. How did NETTER-2 extend the NETTER-1 finding?
Answer: It moved ¹⁷⁷Lu-DOTATATE into the first-line setting for higher-grade (grade 2–3) GEP-NETs.
Key References
- Strosberg J, et al. Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1). N Engl J Med 2017;376:125–135. doi:10.1056/NEJMoa1607427
Evidence & sources
https://nuc.med/netter-1-trial/ Report an issue